Two cannabis-based medicines – manufacturered by GW Pharmaceuticals (NASDAQ:GWPH) – have been recommended for use on the NHS for the first time.
Epidyolex has been approved for two rare types of epilepsy, Lennox-Gastaut and Dravet syndromes, while the spray Sativex has been recommended for muscle spasms in multiple sclerosis.
Campaigners welcomed the decision, but said thousands of other people with a range of conditions who could benefit from cannabis-based medicines were left in limbo.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.